lysophosphatidic acid has been researched along with Parkinsonian Disorders in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, Y; Han, HL; Han, HR; Lin, ZJ; Pan, ZF; Qu, MH; Sun, FX; Yang, XY; Zeng, XW; Zhao, EY; Zhuang, WX | 1 |
1 other study(ies) available for lysophosphatidic acid and Parkinsonian Disorders
| Article | Year |
|---|---|
LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
Topics: Animals; Cell Survival; Central Nervous System Agents; Dopaminergic Neurons; Female; Glial Fibrillary Acidic Protein; Lysophospholipids; Male; Mesenchymal Stem Cells; Myenteric Plexus; Neurogenesis; Oxidopamine; Parkinsonian Disorders; Phosphopyruvate Hydratase; Rats, Sprague-Dawley; Receptors, Lysophosphatidic Acid; Signal Transduction; Substantia Nigra; Tyrosine 3-Monooxygenase | 2015 |